Eli Lilly has resumed sole development and commercialisation rights to a new insulin analogue formerly covered by its diabetes alliance with Boehringer Ingelheim.
The alliance, formed two years ago, centred on four pipeline compounds relevant to major aspects of diabetes treatment.
The basal insulin analogue LY2605541will now progress to clinical trials under Lilly’s sole control.
The two companies are still working together to develop and commercialise three products including Trajenta (linagliptin), a drug for type 2 diabetes.
The partnership aimed to provide a broad portfolio of drugs for people with diabetes, but Lilly has now opted to shift LY2605541to its own drug portfolio.
Lilly will continue with the planned clinical trials of LY2605541, which will support regulatory submissions and evaluate the new drug’s safety, efficacy and differentiation.
Encouraged by the phase 1 and 2 clinical trial data for LY2605541, Lilly hopes to present phase 3 data and gain regulatory approval in 2014.
Enrique Conterno (pictured), President of Lilly Diabetes, said: “Boehringer Ingelheim is an important partner in our strategy to provide a broad portfolio of diabetes medicines, and our diabetes alliance remains strong.
“There is no group of patients with whom Lilly has a deeper history than those impacted by diabetes. If approved, this basal insulin analogue will be an important addition to the Lilly portfolio.”
Eli Lilly, the first company to commercialise insulin, has a long history of innovation in diabetes treatment.